8. Eli Lilly and Company (NYSE:LLY)
Eli Lilly and Company (NYSE:LLY) lands at No. 8 on this list of the Top 10 Stocks That Could Make You a Millionaire Over the Next 3 Years, and this is one of the clearest examples of how healthcare innovation can turn into serious stock market power. Trading at $1,206.51, with the stock up 6.99%, Eli Lilly and Company (NYSE:LLY) has become one of the most dominant pharmaceutical stocks in the market. The company is backed by 132 hedge fund holders, showing that major investors continue to track its long-term growth story. Over the past 30 days, Eli Lilly and Company (NYSE:LLY) has gained roughly 6%, and Wall Street still sees more than 13.6% upside from current levels. For investors searching for healthcare stocks to buy, pharmaceutical stocks, obesity drug stocks, weight loss drug stocks, diabetes treatment stocks, cardiometabolic stocks, and long-term growth stocks, Eli Lilly and Company (NYSE:LLY) remains one of the most powerful names in the market.
The recent optimism around Eli Lilly and Company (NYSE:LLY) was supported by analyst action. On June 25, Leerink analyst David Risinger raised the firm’s price target on Eli Lilly and Company (NYSE:LLY) from $1,119 to $1,232 while maintaining an Outperform rating. Just a few days earlier, on June 22, Berenberg analyst Kerry Holford raised the firm’s price target on Eli Lilly and Company (NYSE:LLY) from $1,050 to $1,135 while keeping a Hold rating on the shares. These price target increases reflect the market’s confidence in the company’s growth engine, especially as demand remains strong for metabolic treatments Mounjaro and Zepbound. Those two drugs have helped turn Eli Lilly and Company (NYSE:LLY) into one of the biggest winners in the global pharmaceutical sector, as obesity and diabetes treatment continue to represent enormous addressable markets.
The trivia behind Eli Lilly and Company (NYSE:LLY) is that its current success is not just about one drug or one trend. The company has spent years building a deep pipeline across cardiometabolic health, oncology, immunology, and neuroscience. Its move into sleep medicine is now attracting fresh attention after the company announced on June 24 that it had completed the acquisition of Centessa Pharmaceuticals, a clinical-stage company focused on developing a new class of medicines for narcolepsy and other sleep-wake disorders. Following the announcement, Eli Lilly and Company (NYSE:LLY) stock gained roughly 1.5%, a sign that investors viewed the transaction as another step in the company’s long-term expansion strategy. Management said Centessa’s work focuses on orexin receptor 2 agonists, which target the orexin system in the brain that helps control wakefulness, alertness, and sleep stability. That may sound technical, but the business point is clear: Eli Lilly and Company (NYSE:LLY) is using its financial strength to broaden its pipeline beyond its already successful metabolic franchise.
This is why Eli Lilly and Company (NYSE:LLY) remains one of the most interesting stocks to watch over the next three years. The company is already a leader in some of the most commercially attractive categories in healthcare, but it continues to push into new areas where demand could expand over time. Its success with Mounjaro and Zepbound has created a massive earnings growth story, while its acquisition activity signals that management is thinking beyond the current product cycle. For investors looking for millionaire-maker stocks, high-growth healthcare stocks, and strong pharmaceutical companies with durable demand, Eli Lilly and Company (NYSE:LLY) offers a rare combination of brand strength, pipeline depth, global scale, and pricing power.
Eli Lilly and Company (NYSE:LLY) develops human pharmaceutical products across cardiometabolic health, oncology, immunology, and other major treatment categories. While valuation remains a real concern because the stock has already delivered strong gains, the company’s growth profile is still one of the strongest in the healthcare sector. If demand for its obesity and diabetes treatments remains strong and its pipeline continues to deliver, Eli Lilly and Company (NYSE:LLY) could remain a core holding for investors seeking exposure to the future of medicine.
Click next to see the following stock...
